<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347773">
  <stage>Registered</stage>
  <submitdate>28/11/2011</submitdate>
  <approvaldate>6/12/2011</approvaldate>
  <actrnumber>ACTRN12611001242910</actrnumber>
  <trial_identification>
    <studytitle>Establishing a comprehensive tissue archive for multi-center prospective longitudinal and cohort studies - Step 1: Prostate cancer - Validation of the HistoBest Biopsy Chip(TM) (patent pending) as a diagnostic tool and enabling technology in the screening for retroviruses, genetic susceptibility and somatic mutations</studytitle>
    <scientifictitle>Evaluation by histopathology examination and immunohistochemistry on TRUS-guided prostate biopsy samples of the presence, location, extension and grade of tumor (Gleason score) in patients with suspicion of prostate cancer</scientifictitle>
    <utrn>U1111-1126-0992</utrn>
    <trialacronym>STOPCANCER</trialacronym>
    <secondaryid>NONE</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>prostate cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>prostate cancer diagnosis via systematic TRUS-guided prostate biopsy (once per patient, lasting ~ 20 min):

- prostate samples are harvested via systematic TRUS-guided biopsy using a Bard MAGNUM (Registered trademark) biopsy gun (Bard Biopsy Systems Inc., Tempe, AZ, USA) and 18G x 20 mm core tissue biopsy needles; 
- local anesthesia is achieved by intrarectal application of 2% lidocaine gel, without periprostatic nerve block;
- in selected cases antibiotic prophylaxis is used, consisting in single dose fluoroquinolone derivatives or amoxicillin administered before the procedure;
- up to 14 biopsy cores per patient are extracted and placed in a HistoBest Biopsy Chip (Trademark) matrix in grooves at specified positions and in the same orientation with respect to the entry point of the biopsy needle;
- the location of each core is marked with a number on a prostate diagram map for each biopsy protocol sheet, allowing unambiguous and easy location of the tumor and estimation of its size and extension.</interventions>
    <comparator>histopathology examination + immunohistochemistry for p63 and Alpha-Methylacyl-CoA Racemase (AMACR) primary antibodies (once only per patient, lasting 3 days):

- processing of biopsy-loaded matrices is performed in a standardized fashion, and consists in: fixation for 24 +/- 2 hours with 0.2 M phosphate-buffered 4% formaldehyde (pH 7.5), dehydration in graded ethanols, optional storage in buthanol, clarifying in transition solvents, infiltration and embedding in paraffin, semi-serial sectioning at 4-5 mm, mounting on positively charged glass slides, and classical hematoxylin-eosin or immunohistochemistry staining</comparator>
    <control>Active</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>presence of cancer (Y/N)</outcome>
      <timepoint>at diagnosis</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>location of cancer (location of positive prostate biopsy cores)</outcome>
      <timepoint>at diagnosis</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>extension of cancer (in mm and % of length of each biopsy core)</outcome>
      <timepoint>at diagnosis</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>grade of cancer (Gleason score)</outcome>
      <timepoint>at diagnosis</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>clinical/biochemical suspicion of prostate cancer
(positive digital rectal examination - DRE and/or
prostate specific antigen - PSA &gt;= 2.5 ng/ml)</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>There are no exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>19/07/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Romania</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>MedNewLife Medical Center</primarysponsorname>
    <primarysponsoraddress>Str. Romulus 57, Bucharest</primarysponsoraddress>
    <primarysponsorcountry>Romania</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>HistoBest Diagnostics S.R.L.</fundingname>
      <fundingaddress>Blvd. Carol I 24, Bucharest</fundingaddress>
      <fundingcountry>Romania</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Genetic Lab</sponsorname>
      <sponsoraddress>Blvd. Ghencea 43B, Bucharest
Ghencea Business Center, 3rd floor</sponsoraddress>
      <sponsorcountry>Romania</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the trial is to assess the effectiveness and safety of a new method for parallel harvesting, processing and analysis of prostate biopsy cores using a new grooved organic matrix, HistoBest Biopsy Chip(TM) (patent pending).
The current hypothesis is that use of this matrix will improve prostate cancer histopathology diagnosis, in several ways:
- by facilitating and encouraging a systematic biopsy approach
- by reducing time and material expenses in processing and analysis of histopathology samples
- by allowing a precise location of the tumor and its extension, because information pertaining to the location and orientation of each biopsy core within the prostate is preserved.

Another goal of the study is to establish a comprehensive tissue archive in view of further studies, such as screening for retroviruses, genetic susceptibility and somatic mutations in prostate cancer.</summary>
    <trialwebsite />
    <publication>Musat S., Farcas C.P., Dumitrescu M., Amuzescu B., Mischianu D.: A multiplex system for processing and analysis of prostate biopsies. Romuro 2011- the 27th National Urology Congress, Timisoara,  26-27 oct 2011, abstract p. 9

Farcas, C.P., Dinu M., Ilie C.P.,  Madan V.,  Popescu R., Spinu D., Amuzescu B., Mischianu D.: The statistical and clinical importance of ERSPC risk indicator in the management of patients with prostate cancer.  Romuro 2011- the 27th National Urology Congress, Timisoara,  26-27 oct 2011, abstract p. 8

Amuzescu B., Farcas C., Mischianu D., Musat S.: A new method for simultaneous processing and analysis of prostate core biopsies, Eur. Urol. - manuscript in preparation</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Local Ethics Committee, "Carol Davila" Central Military Emergency University Hospital, Bucharest</ethicname>
      <ethicaddress>"Carol Davila" Central Military Emergency University Hospital
Str. Mircea Vulcanescu 88, Bucharest</ethicaddress>
      <ethicapprovaldate>14/07/2011</ethicapprovaldate>
      <hrec>104/14/07/2011</hrec>
      <ethicsubmitdate>11/07/2011</ethicsubmitdate>
      <ethiccountry>Romania</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sorin Musat</name>
      <address>HistoBest Diagnostics S.R.L.
Blvd. Carol I 24, Bucharest</address>
      <phone>+40 (0) 768 73 51 94</phone>
      <fax>+40 (0) 21 326 39 96</fax>
      <email>s_musat@yahoo.com</email>
      <country>Romania</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Catalin Farcas</name>
      <address>"Carol Davila" Central Military Emergency Hospital, Str. Mircea Vulcanescu 88, Bucharest</address>
      <phone>+40 (0) 722 228 392</phone>
      <fax>+40 (0) 21 315 51 11</fax>
      <email>catalinfarcasmd@gmail.com</email>
      <country>Romania</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Bogdan Amuzescu</name>
      <address>HistoBest Diagnostics S.R.L.
Blvd. Carol I 24, Bucharest</address>
      <phone>+40 (0) 21 318 15 73</phone>
      <fax>+40 (0) 21 318 15 73</fax>
      <email>bogdan@biologie.kappa.ro</email>
      <country>Romania</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>